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Abstract
Background
Chronic kidney disease (CKD) patients experience a high risk of cardiovascular disease
(CV); however, the factors involved in CV-related morbidity and mortality in these patients
have not been fully defined. Tumor necrosis factor related apoptosis-inducing ligand
(TRAIL) is a cytokine, which exhibits pleiotropic activities on endothelial, vascular smooth
muscle and inflammatory cells, with relevant effects on atheromatous plaque formation. On
this basis, the present study aims to investigate the role of TRAIL in atheromatosis progres-
sion in CKD patients.
Methods
Circulating TRAIL levels were measured in 378 CKD patients belonging to the Spanish
National Observatory of Atherosclerosis in Nephrology (NEFRONA) study. All patients were
free of previous CV events. Carotid and femoral B-mode ultrasound was performed to detect
the presence of plaque at baseline and after 24 months of follow-up.
Results
The lowest levels of TRAIL at baseline were significantly (p<0.05) associated with the
appearance, after 24 months of follow-up, of at least two new atheromatous plaques in all
territories and of one new plaque in the carotid artery, even after adjusting for CV risk fac-
tors. In addition, the patients with low levels of TRAIL at baseline were characterized by the
presence of at least one hypoechoic plaque in the carotid artery. This association was signif-
icant (p<0.05) even after adjusting for CKD stage.
PLOS ONE | https://doi.org/10.1371/journal.pone.0203716 September 11, 2018 1 / 12
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Arcidiacono MV, Rimondi E, Maietti E,
Melloni E, Tisato V, Gallo S, et al. (2018)
Relationship between low levels of circulating
TRAIL and atheromatosis progression in patients
with chronic kidney disease. PLoS ONE 13(9):
e0203716. https://doi.org/10.1371/journal.
pone.0203716
Editor: Tatsuo Shimosawa, International University
of Health and Welfare, School of Medicine, JAPAN
Received: May 28, 2018
Accepted: August 24, 2018
Published: September 11, 2018
Copyright: © 2018 Arcidiacono et al. This is an
open access article distributed under the terms of
the Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: The NEFRONA study was funded by a
research grant from Abbvie and the Spanish
government RETIC (RD16/0009/0011) and FIS
PI16/01354. MVA is the recipient of the Italian
Ministry of Health grant No. GR-2013-02358192.
SG is the recipient of the "Associazione Italiana per
la Ricerca sul Cancro, AIRC" fellowship, No. 18055.
Conclusions
Overall, the results of our study suggest TRAIL as an assertable independent prognostic
biomarker for atheromatosis plaque formation in CKD patients. This observation further sup-
ports the potential role of TRAIL for the prevention/treatment of CV disease.
Introduction
The tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of
the TNF superfamily deeply investigated for its ability to induce apoptosis in tumor cells but
leaving normal cells virtually unaffected in favour of pro-survival pathways activation [1, 2].
TRAIL mediates several pleiotropic effects by virtue of a complex receptor system including
both transmembrane and decoy receptors [3]. Our group has prior investigated the role of
TRAIL in pathological conditions such as acute myocardial infarction, diabetes and hypercho-
lesterolemia, and indicated that circulating levels of TRAIL inversely correlate with all-causes
and cardiovascular mortality [4–14].
Atheromatosis is an inflammatory disorder of the vessel wall in which endothelial cells
(ECs), vascular smooth muscle cells (VSMCs) and inflammatory cells interact with a variety of
soluble mediators, including TRAIL. In this setting, TRAIL, which is involved in antagonistic
processes, modulating activation, apoptosis and/or necrosis of the vascular and inflammatory
cells, exerts either a protective or a pro-atheromatous effect [15]. Indeed, although TRAIL-
mediated apoptosis of ECs could promote atheromatosis [16], TRAIL-mediated induction of
ECs proliferation and of anti-inflammatory effects, with a reduction of monocyte/leukocyte
infiltration into the vessel wall, could exert an overall anti-atherosclerotic effect [17]. A similar
controversial activity has been reported on VSMCs where, at early stages, TRAIL-induced apo-
ptosis might favour the atheromatous process [18], while TRAIL-induced proliferation might
be beneficial promoting plaque stabilization at late stages [19]. Moreover, in atherosclerotic
ApoE-/- mice, TRAIL expression, as well as the expression of its soluble receptor osteoprote-
gerin (OPG), increased in the aortic valves suffering from an accelerating atheromatous pro-
cess and vascular calcification, perhaps due to apoptotic bodies derived from VSMCs [20]. On
the contrary, in the TRAIL-/-/ApoE-/- mouse model, TRAIL resulted being protective against
vascular calcification [21], while in dialysis patients circulating TRAIL levels did not associate
with vascular calcification. Moreover, in in vitro experiments, recombinant TRAIL was able to
induce VSMCs calcification only when cells were treated with phosphate [20].
Accelerated atherosclerosis is a common feature of patients affected by chronic kidney dis-
ease (CKD) and these patients are at higher risk of death from cardiovascular disease (CVD)
compared with the general population [22]. However, the underlying mechanisms linking
CKD to accelerated CVD remain undefined. The predictive value on the progression of plaque
formation of either the classical CVD risk factors (e.g. hypertension, diabetes, dyslipidemia,
and smoking) or of the disease specific features (e.g. bone mineral dysregulation and inflam-
mation) [23–26] is not completely elucidated and emerging soluble factors seem to contribute
to CKD and its complications.
In the light of its controversial implications in the induction/control of the atheromatous
process, understanding the role of TRAIL levels in the progression of atheromatosis is of high
clinical importance, especially in CKD patients free of cardiovascular events. On these bases,
the purpose of the current study was to assess the levels of circulating TRAIL in a population
TRAIL and atheromatosis progression relationship
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affected by CKD, and to investigate potential association with progression of subclinical ather-
omatosis in these patients.
Materials and methods
Study population
The study population included 378 CKD patients at stages 3 and 4–5 from the multicentre and
observational study NEFRONA [27] that consists of a cohort characterized by a high rate of
atheromatosis [27–30]. Age ranged between 22 and 76 years. Patients were recruited from
October 2009 to June 2011 and followed-up at 24 months. All the included patients had no
reported history of CVD (angina pectoris, acute myocardial infarction, ischaemic stroke,
haemorrhagic stroke, abdominal aortic aneurysm and atherosclerosis) at baseline. Further
exclusion criteria included pregnancy, active infections (HIV and tuberculosis), organ trans-
plantations, previous history of carotid artery disease, hospitalization in the last month, and
survival expectation less than 1 year.
The Ethical Committees of all involved Spanish nephrology centres approved this study with
the final approval by the Ethics committee board of the Hospital Universitario Arnau de Vilanova
(Lleida, Spain). The investigation has been conducted according to the principles expressed in the
Declaration of Helsinki, and all the included patients provided written informed consents.
Clinical and biochemical data
At recruitment, performed three months before the vascular exploration, patients informed
about their medical history including diabetes, hypertension, dyslipidemia, and about their
lifestyle habits including smoking and drinking. At the same time, blood was drawn at fasting.
Serum samples were then stored at the centralized biobank of the Spanish Network for
Nephrology Research (REDinREN). Biochemical analysis were performed as described in
Betriu et al. [27], while morphometric parameters were measured as in Arcidiacono et al. [31].
Serum TRAIL concentration was measured with the commercially available Quantikine1
ELISA kit (# DTRL00, R&D Systems) according to the manufacturer’s instructions as previ-
ously described [32, 33].
Carotid and femoral ultrasound
Assessment of the presence and composition of atheromatous plaques was carried out by
carotid and femoral B-mode ultrasound analyses performed at baseline and at 24 months from
the inclusion in the study. A Vivid BT09 Apparatus (GE Healthcare, Waukesha, WI) equipped
with a 6-13MHz broadband linear array probe was used for this assay. Three segments (com-
mon, bulb and internal) of both carotid arteries were explored with the patients in a supine
position and the head 45˚ angled contralateral to the side of the probe. Both common and
superficial femoral arteries were also explored by ultrasound.
In a blinded fashion, a unique reader defined the presence of atheromatous plaques, which
were defined as intima media thickness> 1.5 mm [34, 35], and classified as predominantly
lipidic (type 1 and 2), fibrotic (type 3 and 4) or calcified (type 5) in accordance with their echo-
genicity. The same itinerant team performed the ultrasound exploration, and only one reader
evaluated the ultrasound images.
Statistical analysis
Results were reported as mean±SD for continuous variables with approximate normal distri-
bution, while median and inter-quartile range ([IQR]) were used to describe the other
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numerical variables, instead counts and percentages were used for categorical characters. For
analytical purpose, TRAIL was stratified by tertiles. Comparisons between groups were done
using chi-squared test for categorical variables, while for continuous ones, the ANOVA, the t-
test on means, or the non-parametric Kruskal Wallis and the Wilcoxon-Mann-Whitney tests
were used as appropriate. A first analysis evaluated all the factors that were related to TRAIL
and the progression of the atheromatosis process. Consequently, a regression analysis was per-
formed including all the possible confounding factors that resulted associated to both TRAIL
and outcomes (increasing of plaque number in the carotid and femoral arteries). Poisson
regression was estimated for the outcome “number of new plaques” while logistic regression
model was used for the other dichotomous outcomes. Five nested models were built: simple,
stage adjusted, adjusted for stage and demographics variables, additional adjustment for diabe-
tes and statins treatment. Statistical analysis was done using Stata 13.0 (Stata Corp, College Sta-
tion, TX) statistical program, with a significance level of 0.05.
Results
Association of TRAIL levels with baseline characteristics of the study
population
For the purpose of our study, we have assessed 378 CKD patients, at stages 3 and 4–5, from
the multicentre and observational study NEFRONA. This cohort was chosen because all the
included patients had no reported history of CVD at baseline and therefore represents the
best condition for the identification of predictive markers of CV events. As shown in Fig 1,
at baseline, the circulating levels of TRAIL were significantly (p = 0.003) higher in patients
at CKD stage 4–5 compared to those in patients at CKD stage 3. Based on this difference in
TRAIL levels, we further investigated the association of TRAIL with all the demographic,
clinical, morphometric and biochemical variables (as reported in S1 Table). As expected
[32], diabetes prevalence was significantly (p = 0.023) higher in patients with the lowest lev-
els of TRAIL. In addition, the percentage of patients under statins treatment and the levels
of uric acid were statistically higher in the highest tertile of TRAIL (p = 0.021 and p = 0.001,
respectively). According to the lifestyle habit, smokers were characterized by the lowest lev-
els of TRAIL.
Low TRAIL levels at baseline were associated with higher atherosclerosis
progression
In the next set of analyses, we investigated the association of TRAIL levels at baseline with
atheromatosis progression, assessed in all patients at 24 months follow-up. At baseline, no dif-
ferences in the number of plaques were observed according to the levels of TRAIL. On the con-
trary, after 24 months-follow up the patients with at least two new plaques in all territories
(p<0.02) and one new plaque in the carotid artery (p<0.05) showed the lowest levels of TRAIL
(Fig 2).
Moreover, patients with at least four or more plaques had even lower levels of TRAIL at
baseline (p = 0.033). As expected, additional factors were significantly (p<0.05) associated
with the onset of two or more new plaques at 24 months-follow up (Table 1), such as being
older and male, suffering from diabetes, having high systolic blood pressure (SBP), triglycer-
ides (TG), C-reactive protein (CRP), and high cigarettes and alcohol consumption. In addi-
tion, the lack of statin treatment resulted in two or more new plaques (p<0.05).
Therefore, in order to establish if the level of TRAIL at baseline could be an independent
biomarker of atheromatosis progression, five regression models, including each different set of
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confounding factors associated to both TRAIL and atheromatosis progression were performed
as described in Table 2. Importantly, in comparison with the simple model (OR = 0.72 (0.57–
0.92)), even after adjusting for CKD stage and demographic variables (age, sex and smoking
status), low levels of TRAIL resulted independently associated with the formation of two or
more new plaques (OR = 0.75 (0.59–0.96), p = 0.025). Similar results were observed even when
adjusting for statin treatment only, or adjusting for statin treatment and diabetes further sup-
porting the association between circulating TRAIL levels and the formation of at least two new
plaques in all territories (OR = 0.77 (0.60–0.99), p = 0.046 and OR of 0.78 (0.61–1.00),
p = 0.054, respectively).
Lastly, considering the instability and the role of hypoechoic plaques in contributing to a
higher incidence of CV events, a further analysis explored TRAIL levels in correlation with pla-
que composition. Specifically, the lowest levels of TRAIL were observed in patients with at
least one new hypoechoic plaque after 24 months-follow up in the carotid artery (p = 0.013),
even after adjusting for CKD stage (p = 0.015), a well-recognized factor for plaque
composition.
Fig 1. TRAIL levels stratified by CKD stages at baseline. Box plot graphs showing the levels of TRAIL in patients at
CKD 3 or CKD 4–5 stages. Levels of TRAIL are expressed as median [IQR], minimum and maximum.
https://doi.org/10.1371/journal.pone.0203716.g001
TRAIL and atheromatosis progression relationship
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Discussion
In the present study, conducted on patients affected by CKD at stages 3 to 5 without previous
cardiovascular events, we demonstrated an independent inversely association between the lev-
els of TRAIL and atheromatosis progression. Indeed, low levels of TRAIL statistically signifi-
cant associated with atheromatosis progression even after adjusting for the well-recognized
risk factors for atheromatosis, such as CKD stage, age, sex, and smoking status [27]. Moreover,
the adjustment for diabetes and statin treatments, two established modulators of atheromatosis
progression [30], confirmed that low levels of circulating TRAIL associated to the appearance
of at least two new atheromatous plaques after 24-months of follow-up.
These results further support the involvement of TRAIL on cardiovascular disease since
they are in agreement with previous studies demonstrating that the levels of TRAIL are
reduced in patients with acute coronary syndromes [6, 36], congestive heart failure [37] and in
a CKD population with an elevated risk of mortality [7]. Moreover, our observations indicate a
role of TRAIL as a prognostic factor in CKD patients without previous cardiovascular events
[4].
Although the precise mechanism by which low levels of TRAIL affect the atheromatosis
progression is still unknown, we postulate some potential mechanisms. A first mechanism
could involve VSMCs apoptosis or senescence that has been recently demonstrated promoting
both plaque formation and instability [38]. In fact, previous in vitro experiments demonstrated
that treatment with recombinant TRAIL protected VSMCs from apoptosis [39]. Moreover, in
Fig 2. Association between circulating TRAIL levels and the presence of new atheromatous plaques in all territories and in the carotid artery only.
Box plot graphs showing the levels of TRAIL in patients with or without two new plaques in all territories (carotid and femoral arteries, left panel), or in
patients with or without one new plaque in the carotid artery (right panel) after 24-months follow-up. Levels of TRAIL are expressed as median [IQR],
minimum and maximum.
https://doi.org/10.1371/journal.pone.0203716.g002
TRAIL and atheromatosis progression relationship
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the ApoE-/- mouse model the administration of recombinant TRAIL led to VSMCs prolifera-
tion reducing atheromatosis progression [19]. A further conceivable explanation that cannot
be ruled out is the role of TRAIL in counteracting the proadhesive activity of TNF-α [40]. In
this respect, circulating TRAIL reduction could be the cause of a higher leucocyte adhesion
and infiltration through the endothelial layer leading to atheromatous progression. Impor-
tantly, these data are in part supported by the inverse correlation of the levels of TRAIL and
the presence of at least one unstable hypoechoic plaque in the carotid artery. Indeed, hypoe-
choic plaques are characterized by high prevalence of leucocytes and foam cells and low preva-
lence of VSMCs.
Intriguing is the correlation of incidence of diabetes, smoking, statin treatment and CKD
stage with TRAIL levels. Indeed our results are in accordance with the data of Di Bartolo et al.
Table 1. Clinical, biochemical and morphometric variables associated with the development of at least two new atheromatous plaques.
0–1 new plaque (n = 267) 2 new plaques (n = 111) p-value
Demographic variables
Age (years) 57.3 ± 12.6 61.8 ± 9.8 <0.001
Male (%) 152 (56.9) 76 (68.5) 0.037
Clinical variables
Diabetes (%) 64 (20.0) 43 (38.7) 0.004
CKD stage 4–5 (%) 113 (42.3) 55 (49.6) 0.198
Hypertension (%) 245 (91.8) 102 (91.9) 0.966
Dyslipidemia (%) 175 (65.5) 76 (68.5) 0.583
Morphometric and biochemical variables
BMI (Kg/m2) 28.9 ± 4.9 29.8 ± 5.4 0.106
SBP (mmHg) 138 ± 18 146 ± 20 <0.001
HDL cholesterol (mg/dL) 50.7 ± 14.1 48.2 ± 15.1 0.148
LDL cholesterol (mg/dL) 105.9 ± 32.0 110.7 ± 32.8 0.215
TG (mg/dL)a 119 [88–169] 142 [107–170] 0.023
Creatinine (mg/dL) 2.25 ± 1.09 2.39 ± 1.02 0.267
Glomerular filtration rate (mL/min) 34.4 ± 13.5 32.3 ± 13.1 0.167
Uric acid (mg/dL) 7.1 ± 1.6 7.0 ± 1.7 0.588
Phosphorus (mg/dL)a 3.7 [3.2–4.1] 3.6 [3.2–4.1] 0.933
Ferritin (mg/dL)a 123 [62–216] 114 [58–260] 0.798
CRP (mg/L)a 1.9 [1.0–3.8] 2.9 [1.3–6.4] 0.005
25(OH)-vitamin D3 (ng/L) 18.1 ± 7.9 16.5 ± 6.6 0.056
Hemoglobin (g/dL) 13.2 ± 1.6 13.2 ± 1.9 0.792
Treatments
Statins treatment (%) 159 (59.6) 53 (47.8) 0.035
Antipertensive (%) 249 (93.3) 108 (97.3) 0.118
Lifestyle habits
Smoking status (Current or Former) (%) 140 (52.4) 78 (70.3) 0.001
Alcohol 0.004
>0 <10g 76 (28.5) 23 (20.7)
10<20g 19 (7.1) 20 (18.0)
> = 20g 22 (8.2) 14 (12.6)
aIdentified variables with significant deviations from normal distribution. Values of these variables are provided as median [IQR]. For variables with normal
distribution, values are expressed with mean±SD. BMI: body mass index; SBP: systolic blood pressure; TG: triglycerides; CKD: Chronic Kidney Disease; CRP: C-reactive
protein.
https://doi.org/10.1371/journal.pone.0203716.t001
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[41], in which the incidence of diabetes inversely correlated with TRAIL levels. Moreover, the
concurrence of a low incidence of statin treatment with low levels of TRAIL, and their role on
the development of new atheromatous plaques, indicate either that there is a synergic effect on
plaque formation [42], or that low levels of TRAIL at baseline are a marker of inadequate treat-
ment of dyslipidemia. In fact, in vitro and in vivo studies demonstrated that the lack of TRAIL
increases the levels of cholesterol [41]. The latter hypothesis could improve the managing of
dyslipidemia in CKD at stages 3 to 5 [43]. In addition, although previous mechanistic demon-
strations are unavailable, the inverse association between smoking status and TRAIL leads to
suppose that smoking habit, which is a well-known CV risk factor, could be involved in the
major stages of atherosclerosis through TRAIL modulation. Moreover, higher levels of TRAIL
at baseline in the CKD4-5 population with respect to the CKD3 population could indicate the
worst renal condition of these patients at recruitment, as postulated by Cartland et al. [44].
Nevertheless, in the prospective analysis at 24-months follow up, low levels of TRAIL at base-
line resulted an independent factor for atheromatosis progression. Similar results were
observed in a population with acute myocardial infarction in which only the low levels of
TRAIL at hospitalization, rather than the normal levels after 12-month of follow up, correlated
with a higher incidence of cardiovascular events [6].
Our findings indicate TRAIL as a prognostic factor that deserves further investigation in
larger cohorts of CKD patients at different stages and with a longer follow-up. Certainly, the
strengths of the present study comprise: i) the inclusion of only CKD patients at stages 3 and
4–5 from daily clinical care, resulting in a representative population with the highest athero-
matous mortality risk [27]; ii) the ultrasound exploration done by the same team and evaluated
by the same reader; iii) precise and unique information on plaque morphology.
Conclusions
This work provides the evidence that the level of TRAIL at baseline is an independent prognos-
tic factor for novel atheromatous plaque formation in CKD patients at stages 3 to 5. From a
therapeutic point of view, these results establish the basis for the evaluation of the role of
Table 2. Soluble TRAIL effects on atheromatous progression.
Simple
model
Stage adjusted
model
Stage and demographica adjusted
model
Full adjusted
modelb
Full adjusted
modelc
Number of new plaques in all territoriesc IRR
(95%
CI)
0.86
(0.78–0.95)
0.85
(0.77–0.94)
0.80
(0.81–0.99)
0.91
(0.82–1.01)
0.91
(0.82–1.01)
p-value 0.003 0.001 0.036 0.072 0.084
Presence of at least 2 new plaques in all
territoriesd
OR
(95%
CI)
0.72
(0.57–0.92)
0.70
(0.55–0.89)
0.75
(0.59–0.96)
0.77
(0.60–0.99)
0.78
(0.61–1.00)
p-value 0.008 0.004 0.025 0.046 0.054
Presence of at least 1 new plaque in the
carotid artery
OR
(95%
CI)
0.80
(0.65–0.99)
0.78
(0.63–0.97)
0.83
(0.66–1.04)
0.82
(0.66–1.03)
0.83
(0.66–1.04)
p-value 0.041 0.025 0.099 0.094 0.106
aage, sex and smoking status.
bstage and demographic variables plus statins treatment.
cstage and demographic variables plus diabetes and statins treatment.
dAll territories means carotid and femoral arteries.
https://doi.org/10.1371/journal.pone.0203716.t002
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soluble recombinant TRAIL in preventing/attenuating atheromatous progression in CKD
patients not undergoing dialysis.
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